This tutorial will provide an overview of the main treatment strategies for patients who developed cardiomyopathy as a consequence of cancer therapy. Data from clinical studies and trials will be reviewed and pragmatic management plans will be presented. Furthermore, this tutorial will reflect on cardiotoxicity risk prediction models and evidence-based modes of prevention of cancer therapy-induced cardiomyopathy. Collectively, these efforts are geared to provide the best cardiovascular care to patients with cancer at risk or with established cardiotoxicity as a consequence of their therapy.
- Describe management strategies for patients who developed cardiotoxicity as a consequence of cancer therapy
- Review and apply cardiotoxicity risk prediction models
- Identify medications with proven efficacy for the prevention of cancer therapy-related cardiotoxicity
- Develop a comprehensive cardiovascular care model for cancer patients at risk of cardiotoxicity integrating screening, risk prediction, risk management, and treatment aspects
Joerg Herrmann, M.D.
Associate Professor of Medicine
Division of Cardiovascular Diseases
Mayo Clinic, Rochester, MN
$40 - Streaming Video
$50 - Streaming Video and DVD